Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.47 |
| ▸ | ACACA | Q13085 | 7/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288054 | 1.00 | ACACB (0.47) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL13419702 | 0.95 | ACACB (0.49) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL13419718 | 0.94 | F10 (0.46) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL31333729 | 0.89 | ACACB (0.46) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL13419725 | 0.88 | SIRT2 (0.50) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL31334425 | 0.85 | DRD2 (0.48) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL31334895 | 0.85 | DRD2 (0.62) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL7093978 | 0.85 | CKS1B (0.52) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL4294932 | 0.84 | ALDH1A1 (0.51) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL4294931 | 0.84 | ALDH1A1 (0.51) | ACACBACACACKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | ACACB 3834/4885ACACA 3490/4885CKS1B 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.